How Long Peptides Stay in the Body and Whether They Appear on Drug Tests

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about testing, medication or health. It summarises what published pharmacokinetic and analytical studies reported, and it does not tell anyone what to do.

Answer First: Three Different Clocks

Questions about "how long a peptide stays in the system" usually collapse three separate measurements into one. Keeping them apart explains most of the confusion:

• Circulating half-life — how long it takes plasma concentration to fall by half. For peptides this ranges from minutes to about a week depending on structure.
• Duration of pharmacological action — how long an effect lasts, which can outlive measurable plasma levels, as one tumour-targeting peptide study reported when it assessed disposition and duration of action separately (PMID 36982773).
• Analytical detectability — whether a laboratory using a specific assay can still identify the molecule or a fragment of it. This depends entirely on the sensitivity and design of the assay, not on whether the substance is still doing anything.

A compound can be pharmacologically "finished" and still analytically detectable, or analytically invisible on a panel that was never designed to look for it.

Why Peptides Clear So Differently From One Another

Unmodified peptides are substrates for peptidases in plasma, kidney and gut, and small ones are filtered rapidly by the glomerulus. That is the baseline that pharmaceutical chemistry works against. A review of glucagon-like peptide-1 delivery technologies described how the very short circulating persistence of the native hormone drove the development of analogues, conjugates and alternative delivery routes (PMID 30009885).

Three structural strategies dominate the published literature on extending residence time. Fatty-acid acylation promotes albumin binding: a study of a 1,18-octadecanedioic acid–terlipressin conjugate reported a long-circulating vasoactive peptide compared with the unmodified parent (PMID 38751631). Backbone substitution reduces enzymatic cleavage, a design feature described in the clinical pharmacokinetics of semaglutide (PMID 29915923). Conjugation to larger carriers changes disposition entirely, as reviewed for peptide-drug conjugates and their relationship to antibody-drug conjugates (PMID 40259322).

Reported Half-Lives and Persistence Across Studied Peptides

The table below summarises what the cited papers reported. Every entry is a finding from the linked publication, not a general rule about "peptides".

The spread across that table — minutes to roughly a week — is the single most important point. There is no such thing as "the" peptide clearance time.

How Long Peptides Stay in the Bloodstream

Plasma is where pharmacokinetic sampling happens, so blood is the best-characterised compartment. As a rough convention in pharmacology, a compound is considered largely eliminated after roughly four to five half-lives. Applied to the reported semaglutide half-life of approximately one week, researchers noted that reaching steady state and washing out both take weeks rather than days (PMID 29915923), and the systematic review of semaglutide pharmacokinetics compiled the parameters underlying that timescale (PMID 38952487). At the other extreme, the monograph on tissue plasminogen activator described elimination measured in minutes (PMID 29939694).

Endogenous peptide biology follows the same logic. The review of NT-proBNP explained that a fragment with slower clearance accumulates to higher measured concentrations than its shorter-lived partner peptide even when both are released together (PMID 15948107). Concentration in a sample reflects clearance rate as much as production rate.

Injectable Peptides: Why Route Changes the Timeline

For subcutaneously administered peptides, absorption from the injection depot can become the rate-limiting step, so the apparent elimination profile reflects absorption rather than true clearance. The semaglutide pharmacokinetics review described slow absorption after subcutaneous administration contributing to the extended concentration–time profile (PMID 29915923), and the review of GLP-1 delivery technologies compared subcutaneous, oral and other routes and the formulation work each required (PMID 30009885). The comprehensive incretin review also examined how route and formulation shaped exposure and interaction potential across agents (PMID 40330819).

What the Literature Does — and Does Not — Say About BPC-157

Questions about how long BPC-157 persists are common, and the honest answer from a literature-summary perspective is that the verified papers cited on this page contain no human pharmacokinetic study of BPC-157: no reported half-life, no urinary excretion data, no validated detection window. Nothing on this page should be read as an estimate for it. BPC-157 is not an approved medicine in the United States, is not part of any standard clinical assay panel, and the peptides with published clearance data in the reference list below — semaglutide (PMID 38952487), tirzepatide (PMID 38356317) and others — are structurally unrelated to it, so their numbers do not transfer.

Do Peptides Show Up on Drug Tests?

Standard workplace and clinical urine panels

Routine urine drug screens are built around a defined list of small-molecule drug classes and their metabolites — typically amphetamines, cannabinoids, cocaine metabolite, opiates and phencyclidine, sometimes extended to benzodiazepines, barbiturates and a handful of others. The initial screen is an immunoassay raised against those specific targets, with mass-spectrometry confirmation of presumptive positives. An analyte that no antibody on the panel binds and no confirmation method is calibrated for is simply not among the things the panel measures. This is an analytical-design fact rather than a statement about safety, legality or employment consequences.

Targeted and anti-doping testing

Sport anti-doping is the opposite situation: peptide hormones, growth factors and related substances are explicitly listed on the World Anti-Doping Agency prohibited list, and accredited laboratories run targeted methods designed to find them. Where a dedicated assay exists, detectability depends on that method's sensitivity and on how quickly the compound and its fragments clear. This page is not legal advice; testing rules, employment policy and sport eligibility questions belong with a qualified professional in the relevant jurisdiction or governing body.

Urine versus blood as a matrix

Larger peptides are often degraded before renal filtration, and pieces that do reach urine may be fragments rather than the parent molecule, which means a urine method must be validated against the fragment actually excreted. Published pharmacokinetic programmes therefore usually quantify the parent peptide in plasma, as in the first-in-human study of an aqueous rusfertide formulation in healthy volunteers (PMID 38785334) and the disposition assessment of CEND-1 (PMID 36982773).

How Researchers Measure Where a Peptide Goes

Detection windows in the literature are outputs of laboratory methods, not intrinsic properties of a molecule. Serial plasma sampling with validated bioanalytical assays produced the concentration–time curves behind the population pharmacokinetic model for tirzepatide (PMID 38356317). Radiolabelling gives spatial information instead: a methods chapter described enzymatically catalysed radiofluorination of biomolecules for imaging and tracking studies (PMID 31332755). Conjugate chemistry adds another layer, since a peptide-drug conjugate can release its payload on a different schedule from the carrier, a design consideration reviewed across the PDC field (PMID 40259322).

Stability as a Measurement Variable

Peptides in solution can degrade through hydrolysis, oxidation, deamidation and aggregation, and that degradation changes what an assay measures — a lower reading can reflect a degraded sample rather than faster clearance in the body. This is why formulation work is reported as part of pharmacokinetic studies: the first-in-human rusfertide programme specifically evaluated an aqueous formulation (PMID 38785334), and the review of GLP-1 delivery technologies treated stability and delivery as inseparable from the exposure profile ultimately observed (PMID 30009885). Analytical chemistry, not folklore, defines what "still present" means.

Pharmacokinetic and Tolerability Findings: What Studies Report

Several of the cited papers reported safety or tolerability alongside exposure. The double-blind first-in-human study of rusfertide in healthy volunteers reported tolerability outcomes together with pharmacokinetic and pharmacodynamic measurements (PMID 38785334). The comprehensive review of approved GLP-1 receptor agonists and a dual GLP-1/GIP receptor agonist examined drug–drug interaction potential arising from delayed gastric emptying and related mechanisms (PMID 40330819), and the systematic review of semaglutide pharmacokinetics summarised exposure across populations and study designs (PMID 38952487). None of those findings should be extrapolated to unapproved or research-use-only peptides, which have no comparable published dataset.

Key Points

1. Reported peptide half-lives span minutes to about a week; the class has no single clearance time (PMID 40330819).
2. Duration of action and plasma persistence can diverge, as a disposition study of CEND-1 reported (PMID 36982773).
3. Structural modification — acylation, substitution, conjugation — is the main driver of long circulation, as reported for a terlipressin conjugate (PMID 38751631).
4. Detection requires a purpose-built assay; standard small-molecule drug panels do not include peptide analytes.
5. Where no pharmacokinetic study exists, as with BPC-157 in this reference set, no detection window can be stated.

References

• Clinical Pharmacokinetics of Semaglutide: A Systematic Review (Drug Design, Development and Therapy, 2024)
• Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist (Clinical Pharmacokinetics, 2018)
• A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist (Drug Design, Development and Therapy, 2025)
• Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide (CPT: Pharmacometrics & Systems Pharmacology, 2024)
• Battle of GLP-1 delivery technologies (Advanced Drug Delivery Reviews, 2018)
• NT-ProBNP: the mechanism behind the marker (Journal of Cardiac Failure, 2005)
• Tissue Plasminogen Activator (Archived) (2023)
• Assessment of the Pharmacokinetics, Disposition, and Duration of Action of the Tumour-Targeting Peptide CEND-1 (International Journal of Molecular Sciences, 2023)
• Pharmacokinetics, pharmacodynamics, and tolerability of an aqueous formulation of rusfertide (PTG-300), a hepcidin mimetic, in healthy volunteers: A double-blind first-in-human study (European Journal of Haematology, 2024)
• Long-Circulating Vasoactive 1,18-Octadecanedioic Acid-Terlipressin Conjugate (ACS Pharmacology & Translational Science, 2024)
• Current progress and remaining challenges of peptide-drug conjugates (PDCs): next generation of antibody-drug conjugates (ADCs)? (Journal of Nanobiotechnology, 2025)
• Enzymatically Catalyzed Radiofluorination of Biomolecules (Methods in Molecular Biology, 2019)